SEC Form 4 · accession 0002114309-26-000005
NovaBridge Biosciences · NBP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Cong Claire Xu
Officer — SVP, Clinical Development
Period of report
Jul 4, 2026
Accepted (ET)
Jul 7, 2026 · 7:50 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001778016
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1,F2,F3,F4 | Jul 4, 2026 | M | 12,432 | — | A | 302,586 | D | |
| Ordinary SharesF1,F5,F6,F7 | Jul 6, 2026 | S | 4,485 | $0.89 | D | 298,101 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Share UnitsF8,F3,F9,F1 | — | Jul 4, 2026 | M | 5,405 | D | — | — | Ordinary Shares | 5,405 | 0 | D |
Explanation of responses
- F1The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer.
- F2Reported securities are represented by 5,405 ADSs.
- F3Each restricted stock unit ("RSU") represents a contingent right to receive one ADS.
- F4Reported securities are represented by 131,559 ADSs.
- F5Reported securities are represented by 1,950 ADSs.
- F6Reported sales price represents the converted sales price of the ADSs of $2.04.
- F7Reported securities are represented by 129,609 ADSs.
- F8Reported securities represent ADSs.
- F9Fully vested.